BMS Scoops Cormorant In $520M Immuno-Oncology Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol-Myers Squibb Co. has bolstered its immuno-oncology ambitions by acquiring IL-8 focused Cormorant Pharmaceuticals AB, the 4-year old Swedish biotech. Cormorant’s shareholders are getting $95M up front with the promise of a further $425M if milestones are achieved.